Cargando…

Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency

Multiple pathways have been proposed to generate bradykinin (BK)-related peptides from blood. We applied various forms of activation to fresh blood obtained from 10 healthy subjects or 10 patients with hereditary angioedema (HAE-1 or −2 only) to investigate kinin formation. An enzyme immunoassay for...

Descripción completa

Detalles Bibliográficos
Autores principales: Charest-Morin, Xavier, Hébert, Jacques, Rivard, Georges-Étienne, Bonnefoy, Arnaud, Wagner, Eric, Marceau, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176197/
https://www.ncbi.nlm.nih.gov/pubmed/30333824
http://dx.doi.org/10.3389/fimmu.2018.02183
_version_ 1783361656660688896
author Charest-Morin, Xavier
Hébert, Jacques
Rivard, Georges-Étienne
Bonnefoy, Arnaud
Wagner, Eric
Marceau, François
author_facet Charest-Morin, Xavier
Hébert, Jacques
Rivard, Georges-Étienne
Bonnefoy, Arnaud
Wagner, Eric
Marceau, François
author_sort Charest-Morin, Xavier
collection PubMed
description Multiple pathways have been proposed to generate bradykinin (BK)-related peptides from blood. We applied various forms of activation to fresh blood obtained from 10 healthy subjects or 10 patients with hereditary angioedema (HAE-1 or −2 only) to investigate kinin formation. An enzyme immunoassay for BK was applied to extracts of citrated blood incubated at 37°C under gentle agitation for 0–2 h in the presence of activators and/or inhibitory agents. Biologically active kinins in extracts were corroborated by c-Fos accumulation in HEK 293a cells that express either recombinant human B(2) or B(1) receptors (B(2)R, B(1)R). Biological evidence of HAE diagnostic and blood cell activation was also obtained. The angiotensin converting enzyme inhibitor enalaprilat, without any effect per se, increased immunoreactive BK (iBK) concentration under active stimulation of blood. Tissue kallikrein (KLK-1) and Kontact-APTT, a particulate material that activates the contact system, rapidly (5 min) and intensely (>100 ng/mL) induced similar iBK generation in the blood of control or HAE subjects. Tissue plasminogen activator (tPA) slowly (≥1 h) induced iBK generation in control blood, but more rapidly and intensely so in that of HAE patients. Effects of biotechnological inhibitors indicate that tPA recruits factor XIIa (FXIIa) and plasma kallikrein to generate iBK. KLK-1, independent of the contact system, is the only stimulus leading to an inconsistent B(1)R stimulation. Stimulating neutrophils or platelets did not generate iBK. In the HAE patients observed during remission, iBK formation capability coupled to B(2)R stimulation appears largely intact. However, a selective hypersensitivity to tPA in the blood of HAE patients suggests a role of plasmin-activated FXIIa in the development of attacks. Proposed pathways of kinin formation dependent on blood cell activation were not corroborated.
format Online
Article
Text
id pubmed-6176197
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61761972018-10-17 Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency Charest-Morin, Xavier Hébert, Jacques Rivard, Georges-Étienne Bonnefoy, Arnaud Wagner, Eric Marceau, François Front Immunol Immunology Multiple pathways have been proposed to generate bradykinin (BK)-related peptides from blood. We applied various forms of activation to fresh blood obtained from 10 healthy subjects or 10 patients with hereditary angioedema (HAE-1 or −2 only) to investigate kinin formation. An enzyme immunoassay for BK was applied to extracts of citrated blood incubated at 37°C under gentle agitation for 0–2 h in the presence of activators and/or inhibitory agents. Biologically active kinins in extracts were corroborated by c-Fos accumulation in HEK 293a cells that express either recombinant human B(2) or B(1) receptors (B(2)R, B(1)R). Biological evidence of HAE diagnostic and blood cell activation was also obtained. The angiotensin converting enzyme inhibitor enalaprilat, without any effect per se, increased immunoreactive BK (iBK) concentration under active stimulation of blood. Tissue kallikrein (KLK-1) and Kontact-APTT, a particulate material that activates the contact system, rapidly (5 min) and intensely (>100 ng/mL) induced similar iBK generation in the blood of control or HAE subjects. Tissue plasminogen activator (tPA) slowly (≥1 h) induced iBK generation in control blood, but more rapidly and intensely so in that of HAE patients. Effects of biotechnological inhibitors indicate that tPA recruits factor XIIa (FXIIa) and plasma kallikrein to generate iBK. KLK-1, independent of the contact system, is the only stimulus leading to an inconsistent B(1)R stimulation. Stimulating neutrophils or platelets did not generate iBK. In the HAE patients observed during remission, iBK formation capability coupled to B(2)R stimulation appears largely intact. However, a selective hypersensitivity to tPA in the blood of HAE patients suggests a role of plasmin-activated FXIIa in the development of attacks. Proposed pathways of kinin formation dependent on blood cell activation were not corroborated. Frontiers Media S.A. 2018-10-02 /pmc/articles/PMC6176197/ /pubmed/30333824 http://dx.doi.org/10.3389/fimmu.2018.02183 Text en Copyright © 2018 Charest-Morin, Hébert, Rivard, Bonnefoy, Wagner and Marceau. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Charest-Morin, Xavier
Hébert, Jacques
Rivard, Georges-Étienne
Bonnefoy, Arnaud
Wagner, Eric
Marceau, François
Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
title Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
title_full Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
title_fullStr Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
title_full_unstemmed Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
title_short Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency
title_sort comparing pathways of bradykinin formation in whole blood from healthy volunteers and patients with hereditary angioedema due to c1 inhibitor deficiency
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176197/
https://www.ncbi.nlm.nih.gov/pubmed/30333824
http://dx.doi.org/10.3389/fimmu.2018.02183
work_keys_str_mv AT charestmorinxavier comparingpathwaysofbradykininformationinwholebloodfromhealthyvolunteersandpatientswithhereditaryangioedemaduetoc1inhibitordeficiency
AT hebertjacques comparingpathwaysofbradykininformationinwholebloodfromhealthyvolunteersandpatientswithhereditaryangioedemaduetoc1inhibitordeficiency
AT rivardgeorgesetienne comparingpathwaysofbradykininformationinwholebloodfromhealthyvolunteersandpatientswithhereditaryangioedemaduetoc1inhibitordeficiency
AT bonnefoyarnaud comparingpathwaysofbradykininformationinwholebloodfromhealthyvolunteersandpatientswithhereditaryangioedemaduetoc1inhibitordeficiency
AT wagnereric comparingpathwaysofbradykininformationinwholebloodfromhealthyvolunteersandpatientswithhereditaryangioedemaduetoc1inhibitordeficiency
AT marceaufrancois comparingpathwaysofbradykininformationinwholebloodfromhealthyvolunteersandpatientswithhereditaryangioedemaduetoc1inhibitordeficiency